The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...

Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM ...

Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...

The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, ...

BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a ...

The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...

Heersink School of Medicine have uncovered significant findings regarding the impact of transthyretin, or TTR, protein levels on heart disease risk. The study, recently published in Nature ...

Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.

Intellia Therapeutics, Inc. (NTLA), a clinical-stage gene editing company, Monday said that the U.S. Food and Drug Administration or ...

Briefly, transthyretin (TTR, also known as prealbumin) is a “transporter” protein manufactured by the liver. TTR carries ...

Although some amyloidosis diseases, for example TTR amyloidosis, are caused by the aggregation of a single type of protein, other amyloid diseases are typically characterised by the build-up of ...

Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer ...